期刊文献+

云南省抗病毒治疗病毒学失败的艾滋病患儿的基因型耐药性分析 被引量:8

Analysis of HIV genotypic drug resistance among pediatric HIV/AIDS cases with virological failure after free antiretroviral therapy in Yunnan Province
原文传递
导出
摘要 目的 了解云南省艾滋病儿童患者抗病毒治疗病毒学失败病例的耐药发生情况及耐药基因突变特点.方法 收集云南省2005至2012年接受免费高效抗逆转录病毒治疗(HAART)的人类免疫缺陷病毒(HIV)感染/获得性免疫缺陷综合征(AIDS)患儿的临床及实验室资料,对抗病毒治疗持续6个月以上、病毒载量≥1 000拷贝/ml的患儿进行基因型耐药检测,分析耐药发生情况及耐药毒株流行特点.结果 2005至2012年接受免费HAART的患儿共729例,其中73例患儿发生病毒学失败.73例抗病毒治疗病毒学失败的患儿中耐药基因突变者53例,占病毒学失败患儿的72.6%(53/73),占抗病毒治疗总体人群的7.3%(53/729).耐药突变位点主要为M184V/I[52.1%(38/73)]、K103N[30.1% (22/73)]、T215F/Y[21.9%(16/73)]、G190A[20.5%(15/73)]、Y181C[15.1%(11/73)]和K101E[12.3% (9/73)].在使用过的药物中,对奈韦拉平(NVP)、依非韦伦(EFV)高度耐药的构成比分别为61.6% (45/73)、47.9%(35/73);对拉米夫定(3TC)、齐多夫定(AZT)、司他夫定(D4T)、阿巴卡韦(ABC)高度耐药的构成比分别为54.8% (40/73)、12.3% (9/73)、13.7%(10/73)、5.5% (4/73);只有1例对洛匹那韦/利托那韦(LPV/r)中度耐药.结论 云南省在治的儿童艾滋病患者中,HIV耐药是导致抗病毒治疗失败的主要原因,在当前有限的药物资源环境下,如何最大可能避免耐药的发生与耐药毒株的传播尤为重要. Objective To assess the prevalence and the characteristics of HIV-1 drug-resistance in pediatric HIV/AIDS cases with virological failure after free antiretroviral therapy in Yunnan Province.Methods The data of clinical test and laboratory detection about free antiretroviral therapy in pediatric HIV/AIDS cases from 2005 to 2012 were collected.Then the detection of HIV genotypical drug resistance was performed for the plasmas samples whose viral load were over 1 000 copies/ml after the duration of antiretroviral therapy beyond 6 months.The prevalence and the characteristics of HIV-1 drug resistance were obtained for subsequent analysis.Results A total of 73 cases suffered virological failure among 729 cases while 53 cases exhibited the resistance for antiretroviral drugs.So the resistance ratio was 72.6% (53/73) and the general resistance ratio 7.3% (53/729).The prevalent mutations associated with drug resistance were M184V/I,K103N,T215F/Y,G190A,Y181C and K101E at the frequencies of 52.1% (38/73),30.1% (22/73),21.9% (16/73),20.5% (15/73),15.1% (11/73) and 12.3% (9/73) respectively.The percentage of resistance to NVP,3TC,EFV,D4T,AZT and ABC was 61.6% (45/73),54.8% (40/73),47.9% (35/73),13.7% (10/73),12.3% (9/73) and 5.5% (4/73)respectively.One case developed intermediate resistance to LPV/r.Conclusions The main causes of virological failure is drug resistance.So reducing the incidence and spread of HIV drug resistance is of vital importance in modern era of resource scarcity.
出处 《中华医学杂志》 CAS CSCD 北大核心 2014年第12期884-888,共5页 National Medical Journal of China
基金 国家科技重大专项课题(2012ZX10001-002)
关键词 HIV感染 获得性免疫缺陷综合征 儿童 抗逆转录病毒治疗 高效 抗药性 病毒 HIV infections Acquired immunodeficiency syndrome Child Antiretroviral therapy,highly active Drug resistance,viral
  • 相关文献

参考文献11

  • 1张福杰,王健,王福生,等.国家免费艾滋病抗病毒药物治疗手册[M].3版.北京:人民卫生出版社,2012:183-185. 被引量:68
  • 2李韩平,韩扬,朱新鹏,路新利,郭伟,刘永健,鲍作义,李林,庄道民,刘思扬,李敬云.HIV-1N348I耐药突变流行状况及突变模式的研究[J].中华流行病学杂志,2011,32(9):908-912. 被引量:8
  • 3Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy : a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV-1 Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe [ J]. Lancet ,2000,355 : 1131-1137. 被引量:1
  • 4Rouet F, Fassinou P, Inwoley A, et al. Long-term survival and immuno-vimlogical response of African HIV-l-infected children to highly active antiretroviral therapy regimens [ J ]. AIDS, 2006,20 : 2315-2319. 被引量:1
  • 5李在村,吴昊.HAART在儿童中应用的特殊问题[J].中国艾滋病性病,2008,14(5):528-530. 被引量:6
  • 6Li H, Zhong M, Guo W, et al. Prevalence and mutation patterns of HIV drug resistance from 2010 to 2011 among ART-failure individuals in the Yunnan Province, China[ J]. PLoS One,2013, 8 : e72630. 被引量:1
  • 7Aboulker JP, Babiker A, Chaix ML, et al. Highly active antiretroviral therapy started in infants under 3 months of age:72- week follow-up for CD4 cell count, viral load and drug resistance outcome [ J ]. AIDS,2004,18:237-245. 被引量:1
  • 8Eshleman SH, Krogstad P, Jackson JB, ct al. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitom plus nevirapine, nelfinavir, or r/tonavir(Pediatric AIDS Clinical Tr/als Group 377 ) [ J ]. J Infect Dis,2001.183: 1732-1738. 被引量:1
  • 9赵燕,张福杰,刘志英,程耀武,孙鑫,赵红心.18例抗病毒治疗失败儿童艾滋病患者耐药基因突变规律研究[J].传染病信息,2007,20(6):362-365. 被引量:10
  • 10梁淑家,唐志荣,陈杰,闭志友,梁富雄,李剑军,周崇兴,刘伟.广西16例患AIDS儿童抗病毒治疗病毒学失败者的基因型耐药性研究[J].中国艾滋病性病,2010,16(6):562-564. 被引量:4

二级参考文献48

  • 1张福杰.国家免费艾滋病抗病毒药物治疗手册[M].2版.北京:人民卫生出版社,2008:25-34. 被引量:12
  • 2Martinez-Picado J, Martinez MA. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo. Virus Res,2008,134(1-2) : 104-123. 被引量:1
  • 3Imamichi T,Berg SC,Imamichi H, et al. Relative replication fitness of a high-level 3'-azido-3' -deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr- Gly) at codon 69. J Virol,2000,74(23) : 10958-10964. 被引量:1
  • 4Julias JG, Boyer PL, McWilliams MJ, et al. Mutations at position 184 of human immunodeficiency virus type-1 reverse transcriptase affect virus titer and viral DNA synthesis. Virology, 2004,322( 1 ) : 13-21. 被引量:1
  • 5Nikolenko GN, Palmer S, Maldarelli F, et al. Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc Natl Acad Sci USA,2005,102(6):2093-2098. 被引量:1
  • 6Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One, 2009,4 (3) : e4724. 被引量:1
  • 7Gupta S, Fransen S, Paxinos EE, et al. Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance. Antimicrob Agents Chemother, 2010,54 ( 5 ) : 1973 - 1980. 被引量:1
  • 8Nikolenko GN, Delviks-Frankenberry KA, Palmer S, et al. Mutations in the connection domain of H1V-1 reverse transcriptase increase 3'-azido-3 '-deoxythymidine resistance. Proc Natl Acad Sci USA, 2007,104( 1 ) .. 317-322. 被引量:1
  • 9Betancor G, Puertas MC, Nevot M, et al. Mechanisms involved in the selection of HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with nucleoside analogue therapy failure. Antimicrob Agents Chemother, 2010, 54 ( 11 ) : 4799- 4811. 被引量:1
  • 10Hachiya A, Shimane K, Sarafianose SG, et al. Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naive patients. Antiviral Res, 2009, 82 (3):115-121. 被引量:1

共引文献83

同被引文献63

引证文献8

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部